Alnylam

Phone: +1 617 551 8200

Fax: +1 617 551 8101

Web: https://www.alnylam.com/

Type	Public
Traded as	Nasdaq: ALNY Russell 1000 Component
Industry	Pharmaceutical
Founded	2002
Headquarters	Cambridge, Massachusetts, US
Key people	Yvonne Greenstreet, (CEO)
Revenue	US $219.75 million (2019) US $74.91 million (2018)
Number of employees	1,323 (2019)
Website	alnylam.com

Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, and OXLUMO® (lumasiran) in 2020. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

For detailed contact information visit location pages below.